Examples of 'metabolisers' in a sentence
Meaning of "metabolisers"
Metabolisers are enzymes or substances that facilitate the process of metabolism within living organisms
Show more definitions
- plural of metaboliser
How to use "metabolisers" in a sentence
Basic
Advanced
metabolisers
In poor metabolisers PMs.
None of these analyses were adequately sized to detect differences in outcome in poor metabolisers.
The effects of desloratadine in poor metabolisers < 2 years of age have not been studied.
The TGA has carried out a safety review into codeine use in children and rapid metabolisers.
Less than 1 % of the population are poor metabolisers and have an enzyme with decreased activity.
The exposure of lansoprazole is several-fold higher in PMs than in extensive metabolisers EMs.
Exposure was the same in adult and paediatric poor metabolisers when treated with age-appropriate doses.
In poor metabolisers no measurable levels of O-desmethyl gefitinib were produced.
In practice, voriconazole is administered to both extensive and poor metabolisers without dose adjustment.
In poor metabolisers, active metabolite exposure was decreased by 63-71 % compared to extensive metabolisers.
Plasma concentrations of venlafaxine are higher in CYP2D6 poor metabolisers than extensive metabolisers.
O In CYP2D6 extensive metabolisers ( EMs ) with severe hepatic impairment, Cerdelga is contraindicated.
Glucuronidation and renal excretion are the main mechanisms of elimination in CYP2D6 poor metabolisers.
The effects of Neoclarityn syrup in poor metabolisers < 2 years of age have not been studied.
A few percent of the population have increased CYP2D6 enzyme levels ultrafast metabolisers.
See also
The effects of Aerius syrup in poor metabolisers < 2 years of age have not been studied.
The steady-state pharmacokinetics of umeclidinium bromide were assessed in healthy volunteers lacking CYP2D6 poor metabolisers.
The effects of Azomyr syrup in poor metabolisers < 2 years of age have not been studied.
Define slow, intermediate, extensive and ultra-rapid metabolisers.
The optimal dose regimen for poor metabolisers has yet to be determined see section 5.2.
No dose adjustment is necessary in patients known to be CYP2C9 poor metabolisers.
Patients known to be CYP2C9 poor metabolisers should be treated with caution.
Some of the children were found to be CYP2D6 ultra-rapid metabolisers.
Limited data are available in CYP2D6 extensive metabolisers ( EMs ) with moderate hepatic impairment.
Patients for whom it is known they are CYP2D6 ultra-rapid metabolisers.
The serum Pitolisant half-life was longer in CYP2D6 poor metabolisers compared to the extensive metabolisers.
The steady-state pharmacokinetics of umeclidinium was assessed in healthy volunteers lacking CYP2D6 poor metabolisers.
The eight universal metabolisers are,.
The parameters below reflect mainly the pharmacokinetics in individuals with a functional CYP2C19 enzyme, extensive metabolisers.
The metabolism of darifenacin in CYP2D6 poor metabolisers is principally mediated by CYP3A4.
Estimates indicate that up to I to 2 % of the Caucasian population may be ultra-rapid metabolisers.
Patients known to be CYP2C9 poor metabolisers should be treated with caution see 5.2.
Caution should be used with weak CYP3A inhibitors in poor metabolisers ( PMs ).
Clinical experience in CYP2D6 poor metabolisers ( PMs ) and ultra-rapid metabolisers URMs.
For Caucasians and Blacks the prevalence of poor metabolisers is 3-5.
Other Patients known to be CYP2C9 poor metabolisers should be treated with caution see section 5.2.
CYP2D6 inhibitors used simultaneously with CYP3A inhibitors In intermediate ( IMs ) and extensive metabolisers EMs.
Intermediate metabolisers ( IM ).
The recommended dose is 84 mg eliglustat once daily in CYP2D6 poor metabolisers PMs.
Eliglustat is also contraindicated in patients who are CYP2D6 poor metabolisers taking a strong CYP3A inhibitor.
Vernakalant is mainly eliminated by CYP2D6 mediated O-demethylation in CYP2D6 extensive metabolisers.
Furthermore, the half-life of voriconazole in extensive metabolisers is increased to > 18 hours.
No dose adjustment is necessary in patients known to be CYP2C9 poor metabolisers see section 5.2.
In intermediate ( IMs ) and extensive metabolisers EMs.
A few percent of the population have increased CYP2D6 enzyme levels ( ultrafast metabolisers ) . The information below.
Poor and extensive CYP2D6 metabolisers.
Interactions in CYP2D6 poor metabolisers.
